Navigation Links
Stem cell infusion and hyperbaric oxygen treatment improve islet function in diabetes
Date:3/12/2009

Tampa, Fla. (Mar. 12, 2009) A study to determine if patients with type 2 diabetes can benefit from a combination of autologous (patient self-donated) stem cell infusions (ASC) and hyperbaric (above the normal air pressure of ) oxygen treatment (HBO) before and after ASC has found "significant benefits" in terms of "improvements in glycemic control" along with "reduced insulin requirements." The combination therapy could decrease type 2 diabetes morbidity and mortality, said the authors, who published their study results in the latest issue of Cell Transplantation (Vol. 17 No.12).

"Autologous stem cell therapies are an emerging set of therapies with promising results and low side effects profiles," said corresponding co-author Esteban Estrada, MD, of Stem Cell Argentina. "In addition, hyperbaric oxygen therapy, used primarily in the treatment of carbon monoxide poisoning, air embolism suffered by divers, and as an enhancement to wound healing, has been shown to increase stem cell mobilization and the release of endothelial progenitor cells via a nitric oxide-dependent mechanism."

The clinical trial evaluated the safety of ASC-HBO combination treatment in 25 patients with type 2 diabetes.

According to the researchers, it is well known that with type 2 diabetes, there is an ongoing inflammation of the pancreas. Their hypothesis suggested that mobilizing stem cells would cause the growth of blood vessels (angiogenesis) and release factors that would result in the local differentiation of progenitor cells with a resulting anti-inflammatory effect. Diabetes, they added, has been shown to impair progenitor cell mobilization, a problem that local stem cell infusion could remedy.

Once more, the effect of the hyperbaric oxygen therapy, they hypothesized, would be to increase stem cell mobilization in such a way as "to target more than one crucial reparative step" to counteract the chronic injury that attack the endothelial progenitor cells and the islet cells.

"Overall, our results show that a close follow-up with intensive diabetic management alone could not be the only cause of the positive, progressive and consistent outcomes we obtained in this trial over one year of follow-up," said Dr. Estrada.

"A decade ago, research had explored stem cell transplantation and hyperbaric oxygen therapy as stand alone treatments. This study highlights the potential benefits of using an unusual combination therapy to treat diabetes" said Dr. Cesar V Borlongan, Associate Editor of Cell Transplantation and Professor at the University of South Florida College of Medicine.


'/>"/>

Contact: Camillo Ricordi
ricordi@miami.edu
Cell Transplantation Center of Excellence for Aging and Brain Repair
Source:Eurekalert

Related biology news :

1. Researchers first to see reactive oxygen species in vital enzyme
2. Researchers create new class of fluorescent dyes to detect reactive oxygen species in vivo
3. Drops in blood oxygen levels may be key to sudden death in some epilepsy patients
4. Oxygen depletion: A new form of ocean habitat loss
5. Viruses, oxygen and our green oceans
6. Oregon researchers study widespread areas of low oxygen off northwest coast
7. Crew oxygen for ISS loaded on Jules Verne
8. Why diving marine mammals resist brain damage from low oxygen
9. Researchers detect hint of oxygen 50 to 100 million years earlier than first believed
10. Low oxygen in coastal waters impairs fish reproduction
11. Interventional treatment can be recommended as first-line treatment for silent killer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/17/2016)... , Nov. 17, 2016 Global Market Watch: ... Biobanks (Disease-Based Banks, Population-Based Banks and Academics) market is to ... for Private Biobanks shows the highest Compounded Annual Growth Rate ... region during the analysis period 2014-2020. North ... of 9.95% followed by Europe at ...
(Date:11/15/2016)... 15, 2016  Synthetic Biologics, Inc. (NYSE MKT: ... on the gut microbiome, today announced the pricing ... of its common stock and warrants to purchase ... price to the public of $1.00 per share ... from the offering, excluding the proceeds, if any ...
(Date:11/14/2016)... SANTA CLARA, Calif. , Nov. 14, ... of the biometric identification market, Frost & ... Global Frost & Sullivan Award for Visionary ... leading player in the biometric identification market ... a multi-modal verification solution for instant, seamless, ...
Breaking Biology News(10 mins):
(Date:12/9/2016)... 9, 2016 The research report ... players in the  Global Label-Free Array Systems Market  accounted ... in 2015. Players such as Biacore, Agilent Technologies, ForteBio, ... in the global market due to their unmatched product ... Product upgrades and timely product launches are expected to ...
(Date:12/9/2016)... According to a new market research report "Oligonucleotide Synthesis ... Application (Research, PCR, Gene, DNA, NGS, Diagnostic, RNAI), End user (Academic, ... market is expected to reach USD 2.20 Billion by 2021 from ... the forecast period. Continue Reading ... ...
(Date:12/8/2016)... DIEGO, Dec. 8, 2016  OncoSec Medical Incorporated ... developing DNA-based intratumoral cancer immunotherapies, today announced financial ... "We are delivering on our commitment ... with ImmunoPulse® IL-12. We are pleased with the ... combination trial, and we are focused on advancing ...
(Date:12/8/2016)... , Dec. 8, 2016  Renova™ Therapeutics, ... congestive heart failure and type 2 diabetes, announced ... a novel adeno-associated virus (AAV) vector developed in ... M.D., Ph.D., at Stanford University. The company plans ... paracrine gene therapy product pipeline. ...
Breaking Biology Technology: